The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) oversees pharmaceutical compounds’ compliance with the Human Medicines Regulations 2012, which align closely with EU legislation post-Brexit.

ICH Guidelines: The International Council for Harmonisation (ICH) provides guidelines (e.g., ICH Q8, Q9, and Q10) that set out principles for quality risk management and quality by design, which are critical in ensuring consistent product quality and safety in specialty settings.

Documentation

Documentation plays a critical role in the RA process for compounding and customisation practices. Essential documents include:

• Master Formulation Records (MFR): Detailed records outlining the formulation, preparation, storage conditions, and expiration dates for compounded medications.
• Compounding Records: Specific logs that document each step in the compounding process, including the personnel involved, ingredients used, and environmental conditions during preparation.
• Stability Studies: Documentation that presents the findings of stability testing for compounded preparations, essential for establishing shelf life and storage conditions.
• Quality Assurance (QA) Protocols: Standard Operating Procedures (SOPs) and guidelines to ensure compliance with regulatory standards, encompassing risk assessment and mitigation strategies.

Review/Approval Flow

The review and approval process for compounded medicines involves several stages:

1. Internal Review: This initial phase involves an in-house assessment of the compounded preparation against regulatory standards and internal QA criteria.
2. Regulatory Submission: For 503B outsourcing facilities in the U.S., a report must be submitted to the FDA detailing the compounding practices. In the EU and UK, compliance with relevant guidelines must be documented.
3. Inspections: Regulatory bodies (FDA, EMA, MHRA) may conduct inspections to verify compliance with good manufacturing practices (GMP). These inspections assess facility conditions, procedures, and record-keeping.
4. Post-Approval Monitoring: Ongoing reporting and adherence to relevant adverse event reporting requirements are critical post-approval obligations.

Common Deficiencies

Regulatory agencies frequently identify the following areas of deficiencies during inspections:

• Inadequate Documentation: Missing or incomplete records regarding compounding processes can result in regulatory non-compliance.
• Quality Management Shortcomings: Failure to implement robust quality management systems may lead to product inconsistencies or deviations from established standards.
• Insufficient Training: Personnel involved in compounding must receive adequate training. Gaps in training programs can lead to procedural errors.
• Non-Compliance with Testing Protocols: Skipping required stability or quality testing can jeopardize patient safety and regulatory compliance.

Regulatory Affairs Decision Points

In navigating the complexities associated with compounding and customisation in specialty settings, Regulatory Affairs professionals must consider several key decision points:

When to File as a Variation vs. New Application

Deciding whether to file a variation to an existing marketing authorization or a new application depends on several factors:

• Change in Indication: If the compounded product is intended for a different patient population or clinical indication, a new application may be warranted.
• Significant Change in Formulation: Any substantial alteration to the formulation or method of manufacturing may require a new application.
• Minor Adjustments: If the adjustments are procedural or relate to non-significant quality attributes, a variation may suffice.

Justifying Bridging Data

In instances where a compounded product is modified from an existing reference product, justifying the use of bridging data becomes crucial. Regulatory professionals should:

• Conduct Comparative Studies: Provide robust evidence that supports the safety and efficacy of the compounded product relative to the reference product.
• Establish Pharmaceutical Equivalence: Utilize Bioequivalence (BE) studies to demonstrate that the compounded product performs similarly to the reference.
• Ensure Transparency: Maintain clear and detailed documentation to support claims about the bridging data, including any studies, results, and professional opinions.

Interaction with CMC, Clinical, PV, QA, and Commercial Teams

Effective communication and collaboration among various departments are essential for ensuring compliance in compounding and customisation practices. Key interactions include:

• Chemistry, Manufacturing and Controls (CMC): The CMC team must coordinate with Regulatory Affairs to ensure all quality specifications and stability data are aligned with regulatory expectations.
• Clinical Teams: Regulatory Affairs should liaise with clinical development teams to align on study protocols, especially for investigational drugs that might require compounding.
• Pharmacovigilance (PV): Regular communication is vital to ensure any adverse effects related to compounded medications are promptly reported to regulatory agencies.
• Quality Assurance (QA): QA teams must evaluate compliance with SOPs and regulations, with RO professionals providing necessary documentation during audits and inspections.
• Commercial Teams: Marketing teams should be educated about the regulatory requirements surrounding promotional materials related to compounded products.

Practical Tips for Documentation, Justifications, and Responses to Agency Queries

To enhance compliance and minimize regulatory risks, consider the following best practices:

• Implement a Robust Document Management System: Utilize modern Document Management Systems (DMS) to ensure all records are easily accessible and regularly updated.
• Conduct Regular Training: Establish ongoing training programs for staff involved in compounding to keep them updated on regulatory expectations and internal procedures.
• Engage External Experts: When needed, consult with external regulatory experts to provide guidance on complex compounding issues and interpretation of guidelines.
• Proactive Communication with Regulatory Bodies: Maintain open communication channels with regulatory agencies. Submit inquiries when clarifications on specific health regulations or compliance issues are needed.

Understanding and navigating the regulatory landscape for compounding, customisation, and expanded access in specialty settings is critical for ensuring compliance and safeguarding patient health. Regulatory Affairs professionals must remain diligent in their practices, continually updating knowledge to align with evolving regulations and industry standards.